Psychedelic research in June continued the path towards making psychedelics available as medicines. From those who use mental health services to the general public, everyone has to get on board before we can get there.
Psychedelic research in May saw the MAPS MDMA study data, psychedelics and genes, and many psychedelic center studies.
Psychedelic research in April pitted psychedelics against SSRIs, gave mice a break from tripping, and found new psychedelics. As we’re awaiting the full results of the MAPS Phase III MDMA trial data, let’s look back at the research of last month.
March was another exceptional month for psychedelics research. March 2021 started with the largest microdosing study with psilocybin, LSD, and other psychedelics
It was another great month for psychedelic research. The BIMA study was the first to use MDMA-assisted psychotherapy for alcoholism (AUD)
Psychedelic research in January 2021 continued at the pace set by the last year. Looking back at research done previously, a meta-analytic review found psychedelics to improve the mood of patients with depression.
This December, research looked into many different aspects of the psychedelic experience. A review paper put forth the argument on why psychedelics and nature (relatedness) should go hand in hand. Music during psychedelic-assisted therapy is at least as important and we saw the first investigation of different genres at the very end of this year.
This November proved to be another fruitful month for psychedelic research. Psychedelics are being tested as a treatment for more and more mental ills. As this is done, it becomes ever more evident that psychedelics work on resolving an underlying issue. And that the classification (DSM/ICD) are but mere groups of symptoms that in some ways help us make sense of how mental health disorders manifest.
October was possibly the most active month this year for psychedelic research. Although none of the research might have made the big splash that a big double-blind trail does, these are all building blocks that further the psychedelic field.
Psychedelics are being studied for use with many mental health disorders. This ranges from end-of-life anxiety and depression, to eating disorders, to demoralization in AIDS survivors. What underlies this work is the increased neuronal growth (flexibility in the brain) that psychedelics elicit. This needs to be done in conjunction with therapy though, and that is what most articles this month are about.